Shanghai independently develops the first domestic universal quadrivalent influenza virus split vaccine for people aged 6 months and above, initiating influenza vaccination | vaccination | universal

Release time:Apr 14, 2024 17:48 PM

Shanghai's independently developed domestic first universal quadrivalent influenza virus split vaccine for people aged 6 months and above has recently launched vaccination in Shanghai. It is expected to be promoted throughout the city by the end of August, providing citizens with an additional option to prevent influenza.

It is reported that this vaccine independently developed by Shanghai Biotechnology is the first universal quadrivalent influenza virus split vaccine for people aged 6 months and above in China. It was approved by the National Medical Products Administration for marketing on November 22, last year. The vaccine has achieved unified dosage forms for infants, adolescents, adults, and the elderly for the first time in China, becoming the first exclusive universal quadrivalent influenza vaccine for all age groups in the country.

At the Tianlin Community Health Service Center in Xuhui District, the first batch of vaccination sites, Ms. Yang and her family completed the vaccination with three generations of grandparents. "I heard that babies under the age of 3 can also receive full dose influenza vaccines, and I made an appointment as soon as possible." Ms. Cai, who also came to get vaccinated, said, "After experiencing the epidemic, the whole family has a better understanding of the harm of infectious diseases and the protective effect of vaccines. Getting vaccinated together to do a good job in family protection is still relatively cost-effective."

It is reported that this quadrivalent influenza vaccine has taken the lead in completing clinical studies on the safety and immunogenicity of two full dose quadrivalent influenza vaccines administered to infants and young children aged 6-35 months in China. The research results show that this dose has good immunogenicity and safety in the population aged 6-35 months. At present, the price of this quadrivalent influenza vaccine is 135 yuan/dose. It is recommended to get one dose every flu season for those over 3 years old and two doses for those under 3 years old, with a 4-week interval.


Shanghai independently develops the first domestic universal quadrivalent influenza virus split vaccine for people aged 6 months and above, initiating influenza vaccination | vaccination | universal

Medical experts suggest that getting vaccinated against influenza is an effective way to prevent influenza and reduce flu related severe cases and deaths. Antibodies can be produced after 2-4 weeks of vaccination. Generally, completing vaccination before the arrival of the flu season each year can provide protection.

To minimize the impact of influenza disease as much as possible, it is recommended to prioritize timely vaccination for the following key and high-risk populations: elderly people at home, children, chronic disease patients, infants over 6 months old, family members, and medical staff; Participants and support personnel for large-scale events; Vulnerable populations and employees in crowded places such as elderly care institutions, long-term care institutions, and welfare homes; Key population groups, such as teachers and students in daycare institutions, primary and secondary schools, and other high-risk groups for influenza.

It is also reported that the influenza vaccines approved for market in China include trivalent inactivated influenza vaccine, quadrivalent inactivated influenza vaccine, and trivalent attenuated live vaccine. The trivalent vaccine differs from the tetravalent vaccine in terms of the types of influenza viruses that can be prevented. The latter increases the composition of the B Yamagata vaccine, and recipients can voluntarily choose influenza vaccines that meet the age requirements for vaccination, without priority recommendation.

Why is "Cancer King" immunotherapy ineffective? Fudan Cancer Hospital Reveals New Mechanisms of Immunosuppressive Environment for pancreatic cancer CRIP1 | Tumor | pancreatic cancer
Why is "Cancer King" immunotherapy ineffective? Fudan Cancer Hospital Reveals New Mechanisms of Immunosuppressive Environment for pancreatic cancer CRIP1 | Tumor | pancreatic cancer

Immunotherapy has been proven to achieve significant therapeutic effects in various solid tumors. However, for pancreatic cancer, known as the "king of cancer", immunotherapy has been ineffective. On August 4, Professor Yu Xianjun, Dean of the Cancer Hospital Affiliated to Fudan University, and Shi Si, Associate Professor of Pancreatic Surgery released a research achievement, which first found the key role of cysteine rich protein 1 in shaping the immunosuppressive microenvironment of pancreatic cancer, filled the gap in the research field of immunosuppressive microenvironment of pancreatic cancer, and provided a theoretical basis for precise immunotherapy of pancreatic cancer patients. Ductal adenocarcinoma of the pancreas is the main type of pancreatic cancer, accounting for about 90% of all pancreatic cancer. Due to its high malignancy and poor treatment effectiveness, pancreatic ductal adenocarcinoma has always been one of the most malignant tumors. In recent years, the level of surgical techniques and comprehensive treatment has been achieved

A 14-year-old girl suffers from a rare eye disease and receives support from a public welfare fund. Symptoms of "I haven't looked in the mirror for a long time" | Patient | Public welfare
A 14-year-old girl suffers from a rare eye disease and receives support from a public welfare fund. Symptoms of "I haven't looked in the mirror for a long time" | Patient | Public welfare

A 14-year-old girl has been experiencing symptoms such as protruding pupils, incomplete eye closure, corneal injury, restricted eye movement, and overall fatigue for several years. The physical discomfort and facial abnormalities caused by eye diseases have made her increasingly reticent, and her temperament is vastly different from before. At the Ophthalmology Department of the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, the pupil has been diagnosed with a rare thyroid ophthalmopathy combined with myasthenia gravis, which requires prompt treatment. However, considering the young age of the pupil, conventional hormone and radiation therapy cannot be used. Therefore, Zhou Huifang, Deputy Director of Ophthalmology and thyroid ophthalmology expert, has developed a targeted drug combined with surgical treatment plan for it, and targeted drug treatment will be performed first. Three months ago, I was hospitalized for one week with mydriasis and received intravenous targeted drug treatment. Afterwards, I went home for observation and followed up on time

The municipal eye disease prevention and treatment center launched the dry eye diagnosis and treatment studio, and the incidence rate of dry eye in China is about 21% to 30% of the meibomian gland | dry eye | eye disease
The municipal eye disease prevention and treatment center launched the dry eye diagnosis and treatment studio, and the incidence rate of dry eye in China is about 21% to 30% of the meibomian gland | dry eye | eye disease

According to the Statistics of Chinese Dry Eye Expert Consensus, the incidence rate of dry eye in China is about 21%~30%, and it is estimated that there are at least 300 million patients nationwide. The Dry Eye Diagnosis and Treatment Studio of Shanghai Eye Disease Prevention and Treatment Center was officially launched today. In the future, the studio will continuously improve the dry eye diagnosis and treatment standards, and form standardized diagnosis and treatment concepts and service models. Suitable technologies will be promoted to the community, allowing residents to enjoy convenient dry eye diagnosis and treatment services at their doorstep. Executive Dean and Party Secretary Gao Wei stated that this is also one of the livelihood service measures recently launched by the hospital around high-quality development and meeting the needs of the people. It is reported that dry eye syndrome is a chronic ocular surface disease caused by multiple factors. The instability of the tear film or imbalance of the ocular surface microenvironment caused by abnormal quality, quantity, and dynamics of tears can be accompanied by ocular surface inflammatory reactions, tissue damage, and nerve abnormalities, resulting in various discomforts in the eyes

The Ninth Hospital has taken the lead in formulating the world's first consensus on core indicators for clinical evaluation of dental implants, which has been officially published in clinical practice
The Ninth Hospital has taken the lead in formulating the world's first consensus on core indicators for clinical evaluation of dental implants, which has been officially published in clinical practice

The International Dental Implant Consensus Report, jointly written by the Ninth People's Hospital affiliated with Shanghai Jiao Tong University School of Medicine and renowned universities in the field of dentistry such as Harvard University, University of Zurich, University of Gothenburg, Columbia University, and University of Frankfurt, has recently been jointly published in top journals in the field of dentistry, including Clinical Periodontology and Clinical Dental Implant Research. This consensus has for the first time established an internationally unified core set of indicators for evaluating the clinical effectiveness of dental implants, covering the five key areas of the field of dental implants. It is of milestone significance for carrying out standardized clinical diagnosis, treatment, and research on dental implants. The core evaluation indicators determined by this consensus will become an important benchmark for scholars in the field of dental implants worldwide to conduct high-quality research. The consensus is composed of 8 top international experts in the field of oral implantation

Recently, autologous hematopoietic stem cell therapy was completed in Shanghai, and British girls born in the 1990s have suffered from multiple relapses of blood diseases, including stem cells, peripheral blood, and diseases
Recently, autologous hematopoietic stem cell therapy was completed in Shanghai, and British girls born in the 1990s have suffered from multiple relapses of blood diseases, including stem cells, peripheral blood, and diseases

Recently, Catherine, a British girl born in the 1990s, received autologous peripheral blood hematopoietic stem cell transfusion at the Cancer Center of Shanghai Jiahui International Hospital, and was successfully discharged from the warehouse. She is now on her way back to China after being discharged from the hospital. She is also the first patient at Shanghai Jiahui International Hospital to complete relevant treatments. In 2019, Catherine was diagnosed with Hodgkin's lymphoma in the UK, and after treatment, the disease completely improved. During her work and life in China in 2021, she went to seek medical attention due to multiple enlarged lymph nodes. Pathological biopsy confirmed a recurrence of Hodgkin's lymphoma, and through combined targeted drug treatment, her condition was temporarily under control. Last year in the second half of the year, when the disease recurred, the girl began to use immunotherapy combined with targeted drugs for treatment. Expert evaluation suggests that for young patients with hematological tumors, the risk of recurrence is high and treatment difficulty is increasing in the future. Autologous hematopoietic stem cell therapy is recommended